156 related articles for article (PubMed ID: 30166022)
1. Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
Swami U; Smith M; Zhang J
J Thorac Oncol; 2018 Sep; 13(9):e183-e184. PubMed ID: 30166022
[No Abstract] [Full Text] [Related]
2. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
[TBL] [Abstract][Full Text] [Related]
3. A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.
Khunger M; Velcheti V
J Thorac Oncol; 2017 Jul; 12(7):e96-e97. PubMed ID: 28629548
[No Abstract] [Full Text] [Related]
4. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
[TBL] [Abstract][Full Text] [Related]
5. Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.
Mayoral M; Castañer E; Gallardo X; Andreu M; Dalmau E; Garcia Y
Radiologia (Engl Ed); 2019; 61(6):498-505. PubMed ID: 31300214
[TBL] [Abstract][Full Text] [Related]
6. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.
Gokozan HN; Friedman JD; Schmaier AH; Downes KA; Farah LA; Reeves HM
Clin Lung Cancer; 2019 Sep; 20(5):e560-e563. PubMed ID: 31311716
[No Abstract] [Full Text] [Related]
7. Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature.
Wu L; Yu Y; Zhou J; Wang X; Li J; Wang Y
Immunotherapy; 2020 Sep; 12(13):957-964. PubMed ID: 32686549
[No Abstract] [Full Text] [Related]
8. [A Case of Myocardial and Cutaneous Metastases of Squamous Cell Lung Cancer Post Left Pneumonectomy and Radical Surgery for Cutaneous Metastasis during Nivolumab Therapy].
Watanabe I; Kanauchi N; Watanabe H
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1441-1444. PubMed ID: 30382041
[TBL] [Abstract][Full Text] [Related]
9. Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma.
Oliveira LJC; Gongora ABL; Barbosa FG; Dos Anjos CH; Munhoz RR
J Immunother Cancer; 2018 Nov; 6(1):130. PubMed ID: 30482243
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
[TBL] [Abstract][Full Text] [Related]
11. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
Basak EA; Koolen SLW; Hurkmans DP; Schreurs MWJ; Bins S; Oomen-de Hoop E; Wijkhuijs AJM; Besten ID; Sleijfer S; Debets R; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ
Eur J Cancer; 2019 Mar; 109():12-20. PubMed ID: 30654225
[TBL] [Abstract][Full Text] [Related]
12. Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
Komatsu T; Nakamura K; Kawase A
J Thorac Oncol; 2017 Sep; 12(9):e143-e144. PubMed ID: 28838715
[No Abstract] [Full Text] [Related]
13. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
14. Prolonged response after the discontinuation of nivolumab after resistance to gefitinib.
Sasatani Y; Okauchi S; Ohara G; Kagohashi K; Satoh H
Clin Respir J; 2019 Oct; 13(10):657-658. PubMed ID: 31343829
[No Abstract] [Full Text] [Related]
15. Nivolumab improves survival for patients with advanced lung cancer.
Printz C
Cancer; 2017 Sep; 123(17):3211. PubMed ID: 28833027
[No Abstract] [Full Text] [Related]
16. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
[TBL] [Abstract][Full Text] [Related]
17. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].
Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H
Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
Prescrire Int; 2017 Apr; 26(181):93-94. PubMed ID: 30730658
[No Abstract] [Full Text] [Related]
19. Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma.
Davis A; Mahar A; Wong K; Barnet M; Kao S
Clin Lung Cancer; 2021 Sep; 22(5):e665-e667. PubMed ID: 33349572
[No Abstract] [Full Text] [Related]
20. Immunotherapy for non-small cell lung cancer.
Vafadar S
JAAPA; 2019 Sep; 32(9):37-42. PubMed ID: 31460972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
